drugset
drugset / Trial / NCT04853251

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251 ↗

Phase 4 Recruiting 188 enrolled Genentech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Timeline

Start
2021-12-14
Primary completion
2027-09-30
Completion
2027-10-29

Drugs

EvaluationDrugModalityDoseRoute
Background Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications

wet macular degeneration